Pharmacological inhibitors of cyclin-dependent kinases

Trends in Pharmacological Sciences

Volumn 23, Issue 9, 2002, Pages 417-425

  Knockaert, Marie ^a   Greengard, Paul ^b   Meijer, Laurent ^a  

^a STATION BIOLOGIQUE   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 6 O CYCLOHEXYLMETHYLGUANINE; CITALOPRAM; CYCLIN DEPENDENT KINASE INHIBITOR; FASCAPLYSIN; FLAVOPIRIDOL; INDIRUBIN; NG 97; OL 567; OLOMOUCINE; OXINDOLE; PD 0183812; PURVALANOL B; QUINAZOLINE DERIVATIVE; ROSCOVITINE; STAUROSPORINE; SU 9516; UNCLASSIFIED DRUG;

ALOPECIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CANCER; CELL DIFFERENTIATION; CELL DIVISION; CYTOMEGALOVIRUS; DEGENERATIVE DISEASE; GLOMERULONEPHRITIS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; STROKE; VIRUS INFECTION;

ANIMALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; SIGNAL TRANSDUCTION;

EID: 0036710767     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02071-0     Document Type: Review

References (81)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:2002;309-315.
2. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1:2001;222-231.
3. Fischer P.M. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Discov. Dev. 4:2001;623-634.
4. Hardcastle I.R., et al. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42:2002;325-348.
5. Honma T., et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 44:2001;4615-4627.
6. Honma T., et al. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 44:2001;4628-4640.
7. Knockaert M., et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised ligants. Chem. Biol. 7:2000;411-422.
8. Knockaert M., et al. Intracellular targets of paullones: identification by affinity chromatography using immobilized inhibitor. J. Biol. Chem. 277:2002;25493-25501.
9. Schnier J.B., et al. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. 454:1999;100-104.
10. Kaiser A., et al. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys. 386:2001;179-187.
11. Sielecki T.M., et al. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 43:2000;1-18.
12. Soni R., et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 21:2001;436-446.
13. Damiens E., et al. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 20:2001;3786-3797.
14. Edamatsu H., et al. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyl transferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 19:2000;3059-3068.
15. Matushansky I., et al. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14317-14322.
16. Leost M., et al. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267:2000;5983-5994.
17. Lam, L.T. (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biology 2, research0041.1-0041.11
18. Davis S.T., et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science. 291:2001;134-137.
19. Chen X., et al. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J. Natl. Cancer Inst. 92:2000;1999-2008.
20. Ko J. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21:2001;6758-6771.
21. Li B.S. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J. 21:2002;324-333.
22. Patrick G.N., et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
23. Lee M.S. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
24. Larner A.J. Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders. Expert Opin. Ther. Pat. 9:1999;1359-1370.
25. Dranovsky A., et al. Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol. Aging. 22:2001;517-528.
26. Leclerc S., et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease - a property common to most CDK inhibitors? J. Biol. Chem. 276:2001;251-260.
27. Milton N.G.N. Phosphorylation of amyloid-β at the serine 26 residue by human cdc2 kinase. Neurochemistry. 12:2001;3839-3844.
28. Alvarez A., et al. Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death. FEBS Lett. 459:1999;421-426.
29. Bajaj N.P. Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1:2000;319-327.
30. Nguyen M.D., et al. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron. 30:2002;135-147.
31. Ino H., Chiba T. Cyclin-dependent kinase 4 and cyclin D1 are required for excitotoxin-induced neuronal cell death in vivo. J. Neurosci. 21:2001;6086-6094.
32. Patzke H., Tsai L.H. Calpain-mediated cleavage of the cyclin-dependent kinase 5 activator p39 to p29. J. Biol. Chem. 277:2002;8054-8060.
33. Timsit S., et al. Increased cyclin D1 in vulnerable neurons in the hippocampus after ischaemia and epilepsy: a modulator of in vivo programmed cell death? Eur. J. Neurosci. 11:1999;263-278.
34. Osuga H., et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10254-10259.
35. Sakurai M., et al. Cyclin D1 and cdk4 protein induction in motor neurons after transient spinal cord ischemia in rabbits. Stroke. 31:2000;200-207.
36. Katchanov J., et al. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21:2001;5045-5053.
37. Bibb J.A., et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature. 402:1999;669-671.
38. Bibb J.A., et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 410:1999;376-380.
39. Schang L.M. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs. Antivir. Chem. Chemother. 12:2001;157-178.
40. Bresnahan W.A., et al. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology. 231:1997;239-247.
41. Schang L.M., et al. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74:2000;2107-2120.
42. Davido D.J., et al. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of Herpes simplex virus Type 1 ICP0. J. Virol. 76:2002;1077-1088.
43. Wang D., et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75:2001;7266-7279.
44. Chao S.H., et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275:2000;28345-28348.
45. Chao S.H., Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276:2001;31793-31799.
46. Nelson P.J., et al. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J. Am. Soc. Nephrol. 12:2001;2827-2831.
47. Duensing S., et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10002-10007.
48. Nguyen D.X., et al. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J. Virol. 76:2002;619-632.
49. Doerig C., et al. New approaches to the assessment of protein kinases as drug targets in parasitic protozoa. Trends Parasitol. 18:2002;366-371.
50. Pippin J.W., et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel CDK2 antagonist. J. Clin. Invest. 100:1997;2512-2520.
51. Kip1 safeguards against inflammatory injury. Nat. Med. 4:1998;575-580.
52. Sriram V., Patterson C. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery. Circulation. 103:2001;2414-2419.
53. Ruef J., et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. Circulation. 100:1999;659-665.
54. Brooks E.E., et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272:1997;29207-29211.
55. INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J. Mol. Cell. Cardiol. 33:2001;1493-1504.
56. Mermillod P., et al. High developmental competence of cattle oocytes maintained at the germinal vesicle stage for 24 h in culture by specific inhibition of MPF kinase activity. Mol. Reprod. Dev. 55:2000;89-95.
57. Ponderato N., et al. Bovine oocytes treated prior to in vitro maturation with a combination of butyrolactone I and roscovitine at low doses maintain a normal developmental capacity. Mol. Reprod. Dev. 60:2001;579-585.
58. Gibbons J., et al. Enhanced survivability of cloned calves derived from roscovitine-treated adult somatic cells. Biol. Reprod. 66:2002;895-900.
59. Schulze-Gahmen U., et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins Struct. Funct. Genet. 22:1995;378-391.
60. de Azevedo W.F., et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
61. Gray N., et al. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science. 281:1998;533-538.
62. Chang Y.T., et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6:1999;361-375.
63. Legraverend M., et al. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43:2000;1282-1292.
64. Dreyer M.K., et al. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44:2001;524-530.
65. Arris C.E., et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43:2000;2797-2804.
66. Meijer L., et al. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7:2000;51-63.
67. de Azevedo W.F., et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2735-2740.
68. Lawrie A.M., et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4:1997;796-800.
69. Soni R., et al. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 275:2000;877-884.
70. Barvian M., et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 43:2000;4606-4616.
71. Fry D.W. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin-dependent kinases CDK4 and CDK6. J. Biol. Chem. 276:2001;16617-16623.
72. Bramson H.N., et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 44:2001;4339-4358.
73. Andreani A., et al. Imidazo[2,1-b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis and CDK1/cyclin B inhibition. Anticancer Drug Des. 15:2001;447-452.
74. Hoessel R., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
75. Lane M.E., et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61:2001;6170-6177.
76. Clare P.M., et al. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem. 276:2001;48292-48299.
77. Furet P., et al. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12:2002;221-224.
78. Gussio R., et al. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des. 15:2000;53-66.
79. Shewchuk L., et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43:2000;133-138.
80. Sielecki T.M., et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 11:2001;1157-1160.
81. Dhavan R., Tsai L-H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2:2001;749-759.